Skip to content

Advertisement

BMC Microbiology

Research article
Open Access

Antistaphylococcal and biofilm inhibitory activities of acetyl-11-keto-β-boswellic acid from Boswellia serrata

  • Alsaba F Raja1,
  • Furqan Ali2,
  • Inshad A Khan2,
  • Abdul S Shawl1Email author,
  • Daljit S Arora3,
  • Bhahwal A Shah4 and
  • Subhash C Taneja4
BMC Microbiology201111:54

https://doi.org/10.1186/1471-2180-11-54

©  Raja et al; licensee BioMed Central Ltd. 2011

Received: 24 September 2010

Accepted: 16 March 2011

Published: 16 March 2011

Abstract

Background

Boswellic acids are pentacyclic triterpenes, which are produced in plants belonging to the genus Boswellia. Boswellic acids appear in the resin exudates of the plant and it makes up 25-35% of the resin. β-boswellic acid, 11-keto-β-boswellic acid and acetyl-11-keto-β-boswellic acid have been implicated in apoptosis of cancer cells, particularly that of brain tumors and cells affected by leukemia or colon cancer. These molecules are also associated with potent antimicrobial activities. The present study describes the antimicrobial activities of boswellic acid molecules against 112 pathogenic bacterial isolates including ATCC strains. Acetyl-11-keto-β-boswellic acid (AKBA), which exhibited the most potent antibacterial activity, was further evaluated in time kill studies, postantibiotic effect (PAE) and biofilm susceptibility assay. The mechanism of action of AKBA was investigated by propidium iodide uptake, leakage of 260 and 280 nm absorbing material assays.

Results

AKBA was found to be the most active compound showing an MIC range of 2-8 μg/ml against the entire gram positive bacterial pathogens tested. It exhibited concentration dependent killing of Staphylococcus aureus ATCC 29213 up to 8 × MIC and also demonstrated postantibiotic effect (PAE) of 4.8 h at 2 × MIC. Furthermore, AKBA inhibited the formation of biofilms generated by S. aureus and Staphylococcus epidermidis and also reduced the preformed biofilms by these bacteria. Increased uptake of propidium iodide and leakage of 260 and 280 nm absorbing material by AKBA treated cells of S aureus indicating that the antibacterial mode of action of AKBA probably occurred via disruption of microbial membrane structure.

Conclusions

This study supported the potential use of AKBA in treating S. aureus infections. AKBA can be further exploited to evolve potential lead compounds in the discovery of new anti-Gram-positive and anti-biofilm agents.

Keywords

Minimum Inhibitory ConcentrationMinimum Bactericidal ConcentrationPostantibiotic EffectBoswellic AcidLinalyl Acetate

Background

Nosocomial infections pose a significant threat to patients worldwide. Gram-positive bacterial pathogens are a significant cause of nosocomial infections that are important causes of morbidity and mortality [1]. Gram-positive bacterial pathogens such as Staphylococcus aureus, Streptococcus pneumonia and Enterococcus faecalis are clinically significant and the antibiotic resistance in these pathogens has become one of the major worldwide health problems. The emergence of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE) are the major clinical concerns today [2]. The recent appearance vancomycin-intermediate resistant (VISA) and vancomycin-resistant S. aureus isolates (VRSA) in many countries is the latest development in antibiotic resistance [3]. MRSA has now exerted its own impact upon the mortality rate. The average mortality rate from a recent meta-analysis of 30 studies was ≈36% compared against a mortality rate of ≈24% from septicemia caused by methicillin-susceptible S. aureus [4].

Biofilms are communities of surface-associated microorganisms embedded in a self-produced extracellular polymeric matrix that are notoriously difficult to eradicate and are a source of many recalcitrant infections [5–9]. Staphylococci are known to form biofilms on an implanted medical device or damaged tissues and these biofilms are difficult to disrupt [10]. Biofilm infections are difficult to treat due to their inherent antibiotic resistance [11, 12].

Boswellic acids are the major constituents of the gum derived from the plant Boswellia serrata Roxb. ex Colebr. (family Burseraceae, Syn. B. glabra). The gum resin comprises of β-boswellic acids as the main triterpenic acid along with 11-keto-β-boswellic acids and their acetates [13]. The gum exudate is known for its anti-inflammatory properties in the Ayurvedic system of medicines [14, 15]. The alcoholic extract of the gum is used for the treatment of adjuvant arthritis [16]. It has synergistic effect with glucosamine, an anti-inflammatory and anti-arthritic agent [17]. Acetyl-11-keto-β-boswellic acid (AKBA), a component of the gum exudate is a pentacyclic terpenoid and is reported to be active against a large number of inflammatory diseases [18, 19] including cancer, arthritis, chronic colitis, ulcerative colitis, Crohn's disease, and bronchial asthma [20–22]. In spite of these therapeutic effects of boswellic acids, little is known about their antibacterial activity and the active principle responsible. The aim of this study was to evaluate the antibacterial activity of acetyl-11-keto-β-boswellic acid and its effect on biofilms generated by S. aureus and Staphylococcus epidermidis.

Results

Minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) of boswellic acids

The in vitro antibacterial activities of boswellic acids were tested on a group of clinically significant Gram-positive and Gram-negative bacteria (Table 1). AKBA was the most active of the four boswellic acids against the bacterial pathogens. However the activity of AKBA was limited to Gram-positive bacteria only as its MIC was >128 μg/ml against Escherichia coli ATCC 25292 and Pseudomonas aeruginosa ATCC 27853 (Gram-negative pathogens used in this study). AKBA exhibited MIC ranging from 2-8 μg/ml against all the Gram-positive clinical isolates tested, whereas 11-keto-β-boswellic acid (KBA) and β-boswellic acid (BA) exhibited moderate Gram-positive antibacterial activity (MIC ≈ 8-64 μg/ml). Acetyl-β-boswellic acid (ABA) on the other hand was completely devoid of antibacterial activity upto the tested concentration of 128 μg/ml. All the compounds were bacteriostatic in nature and exhibited an MBC >128 μg/ml. Since AKBA was found to be the most active boswellic acid compound against Gram-positive bacterial pathogens, further in vitro studies were performed on this compound against clinically important S. aureus and S. epidermidis.
Table 1

Antibacterial activity of boswellic acid molecules against bacterial pathogens.

Organisms (CIn)

 

KBA

AKBA

BA

ABA

 
 

Ciprofloxacin

MICa

MICa

MICa

MICa

MBCb

S. aureus ATCC-29213

0.25

16

2

32

>128

>128

MRSA ATCC 3591, (50)

8->16

16-32

2-4

32-64

>128

>128

E. faecalis ATCC 29212, (22)

0.25-16

16-32

4-8

8-16

>128

>128

E. faecium ATCC 8042, (18)

0.25-16

16-32

4-8

8-16

>128

>128

S. epidermidis ATCC 12228,(12)

0.25->16

8-16

4-8

32-64

>128

>128

Vancomycin resistant E. faecalis (10)

>16

8-16

2-8

8-16

>128

>128

E. coli ATCC 25292

0.03

>128

>128

>128

>128

>128

P. aeruginosa ATCC 27853

0.12

>128

>128

>128

>128

>128

MICs and MBCs of boswellic acid molecules were determined using CLSI guidelines against 115 clinical isolates including ATCC strains. aMinimum Inhibitory Concentration (μg/ml); bMinimum Bactericidal Concentration (μg/ml); CI = Clinical isolates; n = number of clinical isolates.

Postantibiotic Effect (PAEs)

The PAE of AKBA was determined on S. aureus ATCC 29213 (Table 2). The PAE induced by AKBA was concentration dependent, with duration 3.0 ± 0.1 h at 1 × MIC while at 2 × MIC it was 4.8 ± 0.1 h. Ciprofloxacin was used as control drug in the study and it exhibited a PAE of 1.4 ± 0.05 h at 1 × MIC while at 2 × MIC it was 2.2 ± 0.1 h (0.5 μg/ml). The PAEs of AKBA were significantly higher than the ciprofloxacin against S. aureus (P < 0.05).
Table 2

PAEs of Acetyl-11-keto-β-boswellic acid against S. aureus ATCC 29213.

Compounds

Mean PAE (h) ± SD on:

 

1 × MIC

2 × MIC

Acetyl-11-keto-β-boswellic acid

3.0 ± 0.1a

4.8 ± 0.1b

Ciprofloxacin

1.4 ± 0.05a

2.2 ± 0.1b

The PAEs were monitored by viable count of S. aureus after 2 h exposure to concentrations equal to MIC and 2 × MIC of antimicrobials (AKBA and ciprofloxacin). Values in the same column followed by the same superscripts are significantly different from each other (P < 0.05; Student's t test). PAE, Post antibiotic effect.

Time-kill kinetic studies

The time-kill kinetic studies of AKBA were performed on S. aureus ATCC 29213 (Figure 1). It showed bacteriostatic activity at all the tested concentrations. The maximum effect of AKBA was observed at 16 and 32 μg/ml exhibiting a ≈2 log10 reduction in the viability of S. aureus cells when compared with non treated controls (P < 0.05) at four and eight times it's MIC over a period of 24 h study.
Figure 1

Effect of AKBA at different concentrations (8, 16 and 32 μg/ml) on the cell viabilty of S. aureus ATCC 29213. S. aureus cells without AKBA served as control. The effect of AKBA was observed bacteriostatic at all tested concentrations when compared with non treated control (P < 0.05) over a period of 24 h study. Each time point represents the mean log10 standard deviations (±SD) of three different experiments performed in duplicate. *, P < 0.05; (Student's t test).

Biofilm inhibition and reduction

AKBA effectively inhibited the formation of S. aureus and S. epidermidis biofilms, with 50% biofilm inhibition concentration (MBIC50) from 16-32 μg/ml (as derived from Figure 2A) which is in the range of 4 × MIC and 8 × MIC respectively. AKBA also effectively eradicated the preformed biofilms. The 50% biofilm reduction concentration (MBRC50) ranged from 32-64 μg/ml for both the bacterial isolates (Figure 2B).
Figure 2

Effect of AKBA on the biofilm formation (A) and preformed biofilm (B) by S. aureus ATCC 29213 and S. epidermidis ATCC 12228. After incubation, the biofilms were stained with crystal violet and the optical density of stained adherent bacteria was determined with a multidetection microplate reader at a wavelength of 595 nm (OD595). The results are expressed as average optical density readings for crystal violet assays compared to growth control. The biofilm of S. aureus and S. epidermidis were significantly inhibited (A) and reduced (B) compared with those of bacteria without AKBA (P < 0.01). Values are mean (±SD) from four independent determinations. *, P < 0.01 (Student's t test).

Effect of AKBA on membrane integrity

In order to investigate the antibacterial action of AKBA on the bacterial membrane integrity, the cell suspension of S. aureus ATCC 29213 was exposed to a concentration of 64 μg/ml AKBA for 60 and 120 min followed by staining with propidium iodide (nucleic acid stain). The AKBA exposure resulted in bacterial cell membrane disruption as evident from the increased uptake of propidium iodide in comparison to the unexposed cells (P < 0.05) (Figure 3). In addition, the membrane leakage assay illustrated the cytoplasmic membrane damage of S. aureus. The amount of 260 and 280 nm absorbing material in S. aureus cell supernatants treated with AKBA (relative to the total released upon complete cell lysis) was 12 and 15% at 90 min while it was 15 and 19% at 120 min respectively (Figure 4), which was significantly higher than the untreated control (P < 0.05).
Figure 3

Uptake of propidium iodide in cell of S. aureus ATCC 29213. Cells of S. aureus were treated with AKBA at 64 μg/ml for 60 and 120 min. Control group included cells untreated with AKBA. AKBA treated cells significantly increases the fluorescence compared with untreated control (P < 0.05). Data represent the mean and standard deviations (±SD) of two different experiments performed in triplicate. *, P < 0.05 (Student's t test).

Figure 4

Effect of AKBA on the leakage of 260 and 280 nm absorbing materials in S. aureus ATCC cells. Control group (treated with lytic enzymes and considered as 100% leakage) and treated with AKBA at 64 μg/ml for 90 and 120 min. No compound added served as untreated control. Values are means (±SD) from three independent determinations. *, P < 0.05 (Student's t test), AKBA treated group compared to untreated control group.

Discussion and conclusion

The gum exudate or the resin obtained from the bark of Boswellia serrata has been widely used by the practitioners of the Indian systems of medicine for various medical conditions such as arthritis, asthma, ulcers, and skin diseases; currently it is being extensively used in various formulations for the treatment of inflammation related disorders [13–15]. The major chemical components of gum resin can be divided into three groups: volatile oils or lower terpenoids, higher terpenoids, and carbohydrates. The higher terpenoids comprises of β-boswellic acids as the main triterpenic acid along with 11-keto-β-boswellic acids and their acetates [23].

The in vitro antibacterial activity results of four boswellic acid compounds revealed AKBA to be the most potent antibacterial compound against Gram-positive pathogens, but it showed no significant antibacterial activity (MIC >128 μg/ml) against the Gram negative bacteria. AKBA exerted bacteriostatic antibacterial activity against S. aureus ATCC 29213 (Figure 1) and exhibited a good PAE of 4.8 h at 2 × MIC concentration. Staphylococci cause a large percentage of catheter associated infections, and like many other pathogens, rather than living as free planktonic cells within the host they tend to form a multilayered community of sessile bacterial cells known as a biofilm on medical implants or damaged tissue [7, 24, 12]. Biofilm infections are difficult to treat due to their inherent antibiotic resistance [7, 12, 25]. AKBA effectively inhibited the staphylococcal biofilm and also reduced the preformed biofilm of these bacterial pathogens (P < 0.01). To our knowledge, this is the first report to provide the evidence that AKBA can prevent as well as reduce the S. aureus and S. epidermidis generated biofilms.

AKBA is reported to be active against a large number of inflammatory diseases, cancer, arthritis, chronic colitis, ulcerative colitis, Crohn's disease, and bronchial asthma [21, 26, 20, 27, 28]. The anticancer activity of AKBA is attributed to the inhibitory effect on the lipoxygenases leading to the inhibition of cell proliferation and induction of apoptosis in tumor cells [29]. There are numerous reports available on the antibacterial activity of oleo-gum resin extracts and oleo-gum resin essential oils from Boswellia spp. (Burseraceae) [30–32]. Weckessera et al. [33] reported the antibacterial activity of Boswellia dry extract and keto-ß-boswellic acid. Their findings revealed that the extract was highly effective against selected aerobic and anaerobic bacteria such as Streptococcus, Corynebacteria, C. perfringens and P. acnes; whereas KBA was not effective against these pathogens, suggesting that the effective components are other boswellic acids or essential oils contained in the extract. In this study, we extensively evaluated the boswellic acids for the antibacterial activity and further for the first time established that AKBA is the single most potent antibacterial compound present in the gum exudates of Boswellia serrata.

We further investigated the effect of AKBA on the bacterial cell membrane integrity through propidium iodide uptake assay. Propidium iodide is fluorescent nucleic acid stain that binds to DNA by intercalating between the bases with little or no sequence preference. It is membrane impermeant and generally excluded from viable cells. The increased uptake of propidium iodide in the AKBA treated cells of S aureus in our study indicated that AKBA altered the cell membrane structure, resulting in the disruption of the permeability barrier of microbial membrane structures. Leakage of cytosolic constituents (260 and 280 nm absorbing materials) from S. aureus cells in the presence 64 μg/ml AKBA over a period of two h was significantly higher than background levels (P < 0.05). These observations indicate that the antimicrobial activity of AKBA results from its ability to disrupt the permeability barrier of microbial membrane structures. The lack of antibacterial activity of AKBA against Gram-negative bacteria may be attributed due to the presence of lipophilic outer membrane. This outer layer of the Gram-negative outer membrane is composed primarily of lipopolysaccharide molecules and forms a hydrophilic permeability barrier providing protection against the effects of highly hydrophobic compounds [34, 35]. This may be the probable explanation of the resistance of Gram-negative bacteria to lipophilic AKBA. Similar observations have been made in other studies also, where lipohilic terpenes such as carvacrol, thymol, eugenol, geraniol, linalyl acetate, (-) menthol and bakuchiol have reported low sensitivities against Gram-negative bacteria [36–38].

Gum resin of boswellia is included in the list of substances Generally Recognized As Safe (GRAS), thereby permitting its use as food additive by US FDA. Boswellic acid extract and AKBA have also been reported to be safe and exert minimal toxicity on human skin cells [39]. The recent study indicates that B. serrata is non-mutagenic in Ames test, and is non-clastogenic in in vitro chromosomal aberration study [40]. Oral preparations of Boswellic serrata extract containing AKBA are sold in the market as over the counter (OTC) anti-inflammatory formulations and are considered to be quite safe [41]. The ancient Indian system of medicine (Ayurveda) claims these preparations to be safe and effective dietary supplement against joint disorders [42, 14, 15]. Preliminary pharmacokinetic studies carried out in humans yielded low concentrations of boswellic acids in plasma [43–45]. In the study reported by Buechele and Simmet [44] AKBA was found in plasma at a concentration of 0.1 μM after the daily intake of 4 × 786 mg Boswellia extract for 10 days. In accordance with the observations made in humans, KBA and AKBA were detected at a concentration of 0.4 and 0.2 μM, respectively; in rat plasma following single oral dose administration of 240 mg/kg Boswellia serrata extract [46]. Further attempts should be made to improve the bioavailability of AKBA through lipid based delivery systems. As the literature suggested that the intake of a high fat meal increases three to fivefold in the plasma concentrations of boswellic acid molecules [47].

In addition to the above reported usage and safety associated with AKBA, the potent antibacterial activity reported in this study warrants that the structure of AKBA can be further exploited to evolve potential lead compounds in the discovery of new anti-Gram-positive and anti-biofilm agents.

Methods

Extraction and isolation of boswellic acid molecules from gum resin of Boswellia serrata

BA, KBA, ABA and AKBA were obtained from Bio-organic Chemistry Division of Indian Institute of Integrative Medicine Jammu, India. The extraction, isolation, and quantification of these compounds from gum resin of Boswellia serrata were described in our previous study [17, 23].

Bacterial strains and culture conditions

The bacterial strains used in this study were S. aureus ATCC 29213, methicillin-resistant S. aureus (MRSA) ATCC 33591, E. faecalis ATCC 29212, E. faecium ATCC 8042, S. epidermidis ATCC 12228, E. coli ATCC 25292, P. aeruginosa ATCC 27853 and 112 isolates of various bacterial pathogens (MRSA 50, E. faecalis 22, E. faecium 18, S. epidermidis 12 and vancomycin resistant E. faecalis 10). All ATCC strains were procured from the American Type Culture Collection (ATCC, Manassas, VA, USA). Clinical isolates of all strains were kindly gifted by Ranbaxy Laboratories Limited, India and Lupin pharmaceutical, Pune, India. The cultures were stored at -70°C in trytone soya broth containing 50% glycerol (vol/vol; Himedia, Mumbai India) and maintained on tryptic soy agar (TSA; Difco Laboratories, Detroit, Mich USA).

Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC)

MIC was determined as per the guidelines of Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) [48]. Briefly, the bacterial suspensions were prepared by suspending 18 h grown bacterial culture in sterile normal saline (0.89% NaCl wt/vol; Himedia, Mumbai India). The turbidity of the bacterial suspension was adjusted to 0.5 McFarland standards (equivalent to 1.5 × 108 colony forming units (CFU)/ml). The boswellic acids stock solutions were prepared in 100% dimethyl sulfoxide (DMSO; Merck, Mumbai India) and 2-fold serial dilutions were prepared in Mueller Hinton Broth (MHB; Difco Laboratories) in 100 μl volume in 96-well U bottom microtiter plates (Tarson, Mumbai, India). The above-mentioned bacterial suspension was further diluted in the MHB and 100 μl volume of this diluted inoculum was added to each well of the plate resulting in the final inoculum of 5 × 105 CFU/ml in the well and the final concentration of boswellic acids ranged from 0.25 to 128 μg/ml. Ciprofloxacin was used as standard antibacterial agent for this study at a concentration ranged from 0.03-16 μg/ml. The plates were incubated at 37°C for 18 h and were visually read for the absence or presence of turbidity. The minimum concentration of the compound concentration showing no turbidity was recorded as MIC. The MBC was determined by spreading 100 μl volume on tryptic soy agar (TSA) plate from the wells showing no visible growth. The plates were incubated at 37°C for overnight.

Time kill assay

S. aureus ATCC 29213 was grown in MHB at 37°C for 24 h. The turbidity of the suspension was adjusted to 0.5 McFarland standard (≈ 1.5 × 108 CFU/ml) in sterile normal saline. Two hundred microliters of this suspension was used to inoculate 20 ml of MHB in conical flasks containing AKBA in the concentration range of 8-32 μg/ml. DMSO controls were also included in the study. The flasks were incubated at 37°C. One hundred microliters samples were taken at 0, 1, 2, 4, 6, 8, 10, and 24 h and the viable counts were determined in triplicate on TSA. Killing curves were constructed by plotting the log10 CFU/ml versus time over 24 h [49].

Postantibiotic Effect (PAE)

The PAEs of the AKBA were assessed by the method described by Craig and Gudmundsson [50]. AKBA was added at the MIC and 2 × MIC to test tubes containing ≈106 CFU/ml of S. aureus ATCC 29213 in MHB broth. After an exposure of 2 h to the AKBA, samples were diluted to 1:1,000 in same medium to effectively remove AKBA. CFU was determined from the sample every hour until visual cloudiness was noted. The PAE was calculated by the equation: PAE = T - C, where T represents the time required for the count in the test culture to increase 1 log10 CFU/ml above the count observed immediately after drug removal and C represents the time required for the count of the untreated control tube to increase by 1 log10 CFU/ml.

Biofilm susceptibility assay

The biofilms of S. aureus ATCC 29213 and S. epidermidis ATCC 12228 were prepared in 96-well flat-bottom polystyrene microtiter plates (Tarson, Mumbai, India), using a previously described method of Wei et al. [51] with a few modifications. This method was similar to the MIC assay for planktonic cells. The bacterial suspensions were prepared from the overnight grown culture and the turbidity of the suspension was adjusted to 0.7 O.D.610 (≈1 × 109 CFU/ml). Twofold serial dilutions of boswellic acids were prepared in 100 μl volume in tryptone soya broth (TSB; Difco laboratories) supplemented with 0.5% glucose in the wells of 96-well flat bottom microtiter plate. Forty microliters of fresh TSB with 0.5% glucose was added to each well, followed by the addition of 60 μl of above bacterial suspension. This resulted in the final inoculum of 6 × 107 CFU/ml in each well: the final concentrations of the compounds ranged from (0.12 to 128 μg/ml). The plate was incubated for 18 h at 37°C. After completion of incubation, the planktonic cells were removed from each well by washing with phosphate buffer saline (Himedia, Mumbai, India). The biofilms were fixed with methanol for 15-30 min, stained with 0.1% (wt/vol) Crystal Violet (Sigma Chemical Co., St Louis, MO, USA) for 10 min and rinsed thoroughly with water until the negative control wells appeared colorless. Biofilm formation was quantified by the addition of 200 μl of 95% ethanol to the crystal violet stained wells and recording the absorbance at 595 nm (A595) using a microplate reader (Multiskan spectrum, Thermo electron, Vantaa, Finland).

The effect of AKBA was also examined on preformed biofilms. The biofilms were prepared by inoculating the suspension of S. aureus and S. epidermidis into the wells of a polystyrene microtiter plate as mentioned above. After incubation at 37°C for 18 h, the culture supernatant from each well was decanted and planktonic cells were removed by washing the wells with PBS (pH 7.2). Two fold serial dilution of AKBA was prepared in TSB and 200 μl of each dilution was added to the biofilm in the wells. The plate was further incubated at 37°C for 18 h. The biofilm was fixed, stained and quantified as described above.

Propidium iodide uptake assay

The action of AKBA on cell membrane permeability of S. aureus ATCC 29213 cells was evaluated by the method as described by Cox et al. [52]. The bacterial cells were grown overnight in 100 ml of MHB at 37°C, washed and resuspended in 50-mmol/l sodium phosphate buffer, pH 7·1. The turbidity of the suspension was adjusted to 0.7 O.D.610 (≈1 × 109 CFU/ml). One milliliter volume of this suspension was added to flask containing 19 ml buffer and 64 μg/ml of AKBA. Following 60 and 120 min incubation at room temperature, 50 μl aliquots were transferred into Eppendorfs tubes containing 950 μl phosphate buffer in FACS tubes (Becton Dickinson Biosciences, CA, USA). These tubes were stored on ice and 5 μl of staining solution, consisting of 2.5 mg/ml propidium iodide (Sigma) dissolved in milliQ water, was added in the final propidium iodide concentration of 10 μg/ml. The cells were subjected to FACS analysis [53, 54], on the flow cytometer (BD-LSR, Becton Dickinson).

Leakage of 260 and 280 nm absorbing compounds

The release of 260 and 280 nm absorbing compounds was determined spectrophotometrically [55]. Briefly, cells suspensions of S. aureus were prepared as for propidium iodide uptake assay. AKBA was added at 64 μg/ml to the bacterial suspension (≈1 × 109 CFU/ml) and incubated for 120 min at 37°C. For the complete release of 260 and 280 nm absorbing compounds, the bacterial suspension (control) was treated with lysozyme (100 μg/ml) at 37°C for 120 min, followed by sonication. Cell supernatants were obtained by centrifugation (10,000 g for 10 min). The absorbance of cell supernatant at 260 and 280 nm was determined using spectrophotometer (Multiskan Spectrum). Background leakage rates (no compounds added) were used as untreated control. The extent of leakage of 260 and 280 nm absorbing compounds was expressed as percentage of control (suspension treated with lysozyme) measured in supernatants.

Statistical analysis

All experiments were carried out in triplicates in at least three different occasions. Differences between two means were evaluated by the Student's t-test. The data were analyzed by one-way ANOVA for comparison of multiple means followed by post bonferroni test using GraphPad Instat2 program (GraphPad software Inc. San Diego CA). The chosen level of significance for all statistical tests was P < 0.05.

Declarations

Acknowledgements

The authors thankfully acknowledge the Ranbaxy Laboratories Limited, India for providing clinical Isolates. We would like to thank Scientific Faculty members of IIIM Srinagar, for critical reading of the manuscript. This work was funded by the Council of Scientific and Industrial Research, New Delhi, India (research grant no. P-81-101/2010 SRF (A.F.R.).

Authors’ Affiliations

(1)
Microbiology Unit, Indian Institute of Integrative Medicine (CSIR), Sanatnagar, India
(2)
Clinical Microbiology Division, Indian Institute of Integrative Medicine (CSIR), Jammu, India
(3)
Department of Microbiology, Guru Nanak Dev University, Amritsar, India
(4)
Bioorganic Chemistry, Indian Institute of Integrative Medicine (CSIR), Jammu, India

References

  1. Tacconelli E, Angelis GD, Cataldo AM, Pozzi E, Cauda R: Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother. 2008, 61: 26-38. 10.1093/jac/dkm416.PubMedView ArticleGoogle Scholar
  2. Millar BC, Prendergast BD, Moore JE: Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis. J Antimicrob Chemother. 2008, 61: 1-7. 10.1093/jac/dkm410.PubMedView ArticleGoogle Scholar
  3. Hiramatsu K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001, 1: 1470-55. 10.1016/S1473-3099(01)00091-3.View ArticleGoogle Scholar
  4. Dancer SJ: The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2008, 61: 246-253. 10.1093/jac/dkm465.PubMedView ArticleGoogle Scholar
  5. Brown MR, Allison DG, Gilbert P: Resistance of bacterial biofilms to antibiotics: a growth-rate related effect?. J Antimicrob Chemother. 1998, 22: 777-780. 10.1093/jac/22.6.777.View ArticleGoogle Scholar
  6. Chambers HF: The changing epidemiology of Staphylococcus aureus. Emerg. Infect Dis. 2001, 17: 178-182.View ArticleGoogle Scholar
  7. Stewart PS: Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbio. 2002, 292: 107-113. 10.1078/1438-4221-00196.View ArticleGoogle Scholar
  8. Shirtliff ME, Mader JT, Camper AK: Molecular interactions in biofilms. Chem Biol. 2002, 9: 859-865. 10.1016/S1074-5521(02)00198-9.PubMedView ArticleGoogle Scholar
  9. Adam B, Baillie GS, Douglas LJ: Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol. 2002, 51: 344-349.PubMedView ArticleGoogle Scholar
  10. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF: Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces. Antimicrob Agents Chemother. 2003, 47: 3407-3414. 10.1128/AAC.47.11.3407-3414.2003.PubMedView ArticleGoogle Scholar
  11. Costerton J: Introduction to biofilm. Inter J Antimicro Agents. 1999, 11: 217-221. 10.1016/S0924-8579(99)00018-7.View ArticleGoogle Scholar
  12. Donlan RM, Costerton JW: Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002, 15: 167-193. 10.1128/CMR.15.2.167-193.2002.PubMedView ArticleGoogle Scholar
  13. Yuan G, He G, Yang ML: Natural products and anti-inflammatory activity. Asia Pacific J Clin Nutrition. 2006, 15: 143-152.Google Scholar
  14. Kirtikar KR, Basu BD: In Indian Medicinal Plants. 1935, M/s Periodical Experts. Delhi, India, I: 521-2Google Scholar
  15. Chatterjee GK, Pal SD: Anti-inflammatory agents from Indian medicinial Plants. Indian Drugs. 1984, 21: 431-Google Scholar
  16. Moore PD: Conservation biology: Unkind cuts for incense. Nature. 2006, 444: 829-10.1038/444829a.PubMedView ArticleGoogle Scholar
  17. Singh S, Khajuria A, Taneja SC, Khajuria RK, Singh J, Qazi GN: Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. Bioorg Med Chem Lett. 2007, 17: 3706-3711. 10.1016/j.bmcl.2007.04.034.PubMedView ArticleGoogle Scholar
  18. Safayhi H, Sailer ER, Ammon HP: Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995, 47: 1212-1216.PubMedGoogle Scholar
  19. Safayhi H, Rall B, Sailer ER, Ammon HP: Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther. 1997, 281: 460-463.PubMedGoogle Scholar
  20. Krieglstein CF, Anthoni C, Rijcken EJ, Laukotter M, Spiegel HU, Boden SE, Schweizer S, Safayhi H, Senninger N, Schurmann G: Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis. 2001, 16: 88-95. 10.1007/s003840100292.PubMedView ArticleGoogle Scholar
  21. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R: Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol. 2001, 39: 11-17. 10.1055/s-2001-10708.PubMedView ArticleGoogle Scholar
  22. Kimmatkar N, Thawani V, Hingorani L, Khiyani R: Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomed. 2003, 10: 3-7. 10.1078/094471103321648593.View ArticleGoogle Scholar
  23. Pardhy RS, Bhattacharya SC: Boswellic acid, acetyl- b-boswellic, acid-11- keto-b-boswellic acid and 11-keto-β-boswellic acids from the resin of Boswellia serrata Roxb. Ind J Chem. 1978, 16B: 176-178.Google Scholar
  24. Costerton J, Stewart P, Greenberg E: Bacterial biofilms: a common cause of persistent infections. Science. 1999, 284: 1318-1322. 10.1126/science.284.5418.1318.PubMedView ArticleGoogle Scholar
  25. Dunne WM: Bacterial adhesion: seen any good biofilms lately?. Clin Microbiol Rev. 2002, 15: 155-166. 10.1128/CMR.15.2.155-166.2002.PubMedView ArticleGoogle Scholar
  26. Gupta I, Parihar A, Singh GB, Ludtke R, Safayhi H, Ammon HP: Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997, 2: 37-43.PubMedGoogle Scholar
  27. Reddy GK, Dhar SC: Effect of a new non-steroidal anti-inflammatory agent on lysosomal stability in adjuvant induced arthritis. Ital J Biochem. 1987, 36: 205-217.PubMedGoogle Scholar
  28. Sharma ML, Bani S, Singh GB: Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. Int J Immunopharma. 1989, 11: 647-652. 10.1016/0192-0561(89)90150-1.View ArticleGoogle Scholar
  29. Anderson KM, Seed T, Plate JM, Jajeh A, Meng J, Harris JE: Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leukotr Res. 1993, 19: 789-801. 10.1016/0145-2126(95)00043-7.View ArticleGoogle Scholar
  30. Abdallah EM, Khalid AS, Ibrahim N: Antibacterial activity of oleo-gum resins of Commiphora molmol and Boswellia papyrifera against methicillin resistant Staphylococcus aureus (MRSA). Sci Res Essay. 2009, 4: 351-356.Google Scholar
  31. Camarda L, Dayton T, Di Stefano V, Pitonzo R, Schillaci D: Chemical composition and antimicrobial activity of some oleo gum resin essential oils from Boswellia spp. (Burseraceae). Ann Chim. 2007, 97 (9): 837-44. 10.1002/adic.200790068.PubMedView ArticleGoogle Scholar
  32. Kasali AA, Adio AM, Kundaya OE, Oyedeji AO, Eshilokun AO, Adefenwa M: Antimicrobial activity of the essential oil of Boswellia serrata Roxb. J Essent Oil Bearing Plants. 2002, 5 (3): 173-175.Google Scholar
  33. Weckessera S, Engela K, Simon-Haarhausa B, Wittmerb A, Pelzb K, Schemppa CM: Screening of plant extracts for antimicrobial activity against bacteria and yeasts with dermatological relevance. Phytomedicine. 2007, 14: 508-516. 10.1016/j.phymed.2006.12.013.View ArticleGoogle Scholar
  34. Hancock RE: The bacterial outer membrane as a drug barrier. Trends Microbiol. 1997, 5: 37-42. 10.1016/S0966-842X(97)81773-8.PubMedView ArticleGoogle Scholar
  35. Helander IM, Alakomi HL, Latva-Kala K, Mattila-Sandholm T, Pol I, Smid EJ, Gorris LJ, Von Wright T: Characterization of the action of selected essential oil components on Gram-negative bacteria. J Agric Food Chem. 1998, 46: 3590-3595. 10.1021/jf980154m.View ArticleGoogle Scholar
  36. Gallucci MN, Oliva M, Casero C, Dambolena J, Luna A, Zygadlob J, Demo M: Antimicrobial combined action of terpenes against the food-borne microorganisms Escherichia coli, Staphylococcus aureus and Bacillus cereus. Flavour Fragr J. 2009, 24: 348-354. 10.1002/ffj.1948.View ArticleGoogle Scholar
  37. Trombetta D, Castelli F, Grazia MS, Venuti V, Cristani M, Daniele C, Saija A, Mazzanti G, Bisignano G: Mechanisms of Antibacterial Action of Three Monoterpenes. Antimicrob Agents Chemother. 2005, 49: 2474-2478. 10.1128/AAC.49.6.2474-2478.2005.PubMedView ArticleGoogle Scholar
  38. Reddy MV, Thota N, Sangwan PL, Malhotra P, Ali F, Khan IA, Chimni SS, Koul S: Novel bisstyryl derivatives of bakuchiol: targeting oral cavity pathogens. Eur J Med Chem. 2010, 45: 3125-3134. 10.1016/j.ejmech.2010.03.049.PubMedView ArticleGoogle Scholar
  39. Burlando B, Parodi A, Volante A, Bassi AM: Comparison of the irritation potentials of Boswellia serrata gum resin and of acetyl-11-keto-boswellic acid by in vitro cytotoxicity tests on human skin-derived cell lines. Toxicol Lett. 1993, 177: 144-149. 10.1016/j.toxlet.2008.01.008.View ArticleGoogle Scholar
  40. Magesh V, Raman D, Pudupalayam KT: Genotoxicity studies of dry extract of Boswellia serrata. Tropical J Pharmaceutical Research. 2008, 7 (4): 1129-1135.View ArticleGoogle Scholar
  41. Shah BA, Kumar A, Gupta P, Sharma M, Sethi VK, Saxena AK, Singh J, Qazi GN, Taneja SC: Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. Bioorg Med Chem Lett. 2007, 17: 6411-6416. 10.1016/j.bmcl.2007.10.011.PubMedView ArticleGoogle Scholar
  42. Ammon HP, Safayhi H, Mack T, Sabieraj J: Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol. 1993, 38: 113-119. 10.1016/0378-8741(93)90005-P.PubMedView ArticleGoogle Scholar
  43. Abdel TM, Kaunzinger A, Bahr U, Karas M, Wurglics M, SchubertZsilavecz M: Development of a high performance liquid chromatographic method for the determination of 11 keto beta boswellic acid in human plasma. J Chromatogr Biomed Appl. 2001, 761: 221-227. 10.1016/S0378-4347(01)00335-8.View ArticleGoogle Scholar
  44. Buechele B, Simmet T: Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high performance liquid chromatography and photodiode array detection. J Chromatogr. 2003, 795: 355-362. 10.1016/S1570-0232(03)00555-5.Google Scholar
  45. Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R: Pharmacokinetic study of 11 keto beta boswellic acid. Phytomedicine. 2004, 11: 1255-1260. 10.1078/0944-7113-00290.View ArticleGoogle Scholar
  46. Reising K, Meins J, Bastian B, Eckert G, Mueller WE, Schubert-Zsilavecz M, Abdel Tawab M: Determination of boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem. 2005, 77: 6640-6645. 10.1021/ac0506478.PubMedView ArticleGoogle Scholar
  47. Sterk V, Buchele B, Simmet T: Effect of food intake on the bioavaliability of boswellic acids from an herbal preparation in healthy volunteers. Planta Med. 2004, 70: 1155-1160. 10.1055/s-2004-835844.PubMedView ArticleGoogle Scholar
  48. Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. M7-A7. 2006, Wayne, PA: CLSI, 7Google Scholar
  49. Eliopoulus GM, Moellering RCJ: Antimicrobial combinations. Antibiotics in Laboratory Medicine. Edited by: Lorian V. 1996, Baltimore, MD: The Williams & Wilkins Co, 330-396. 4Google Scholar
  50. Craig WA, Gudmundsson S: Postantibiotic effect. Antibiotics in laboratory medicine. Edited by: Lorian V. 1996, Williams and Wilkins Co., Baltimore, MD, 296-329. 4Google Scholar
  51. Wei GX, Campagna AN, Bokek LA: Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J Antimicrob Agents. 2006, 57: 1100-1109. 10.1093/jac/dkl120.View ArticleGoogle Scholar
  52. Cox SD, Mann CM, Markham JL, Bell HC, Gustafson JE, Warmington JR, Wyllie SG: The mode of antimicrobial action of the essential oil of Melaleuca alternifolia (tree oil). J App Microbio. 2000, 88: 170-175. 10.1046/j.1365-2672.2000.00943.x.View ArticleGoogle Scholar
  53. Lo'pez-Amoro's R, Comas J, Vives-Rego J: Flow cytometric assessment of Escherichia coli and Salmonella typhimurium starvation-survival in seawater using rhodamine 123, propidium iodide, and oxonol. Appl Environ Microbiol. 1995, 61: 2521-2526.Google Scholar
  54. Hilliard JJ, Goldschmidt RM, Licata L, Baum EZ, Bush K: Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob Agents Chemother. 1999, 43: 1693-1699.PubMedGoogle Scholar
  55. Cox SD, Mann CM, Markham JL, Gustafson JE, Warmington JR, Wyllie SG: Determining the Antimicrobial Actions of Tea Tree Oil. Molecules. 2001, 6: 87-91. 10.3390/60100087.View ArticleGoogle Scholar

Copyright

© Raja et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Microbiology

ISSN: 1471-2180

Contact us